FDA escalates crackdown on pharmaceutical advertising with new warning letters
The FDA has issued around 100 warning letters to pharma and biotech companies for misleading direct-to-consumer drug advertisements, highlighting specific ads that falsely suggest benefits, downplay risks, or use attention-grabbing visuals that impair understanding, as part of increased enforcement efforts.